All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2025-02-28.
From the record
Spero Therapeutics, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2025-02-28) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+80.1% a year over 10 filed years; profitable in 2 of 10.
From the record
Spero Therapeutics, Inc.'s 10 filed years say what it did: revenue went from $335 thousand in fiscal 2016 to $67 million in fiscal 2025, up 80.1% a year; it rose in 7 of 9 years; the deepest fall was 54% from fiscal 2023 to fiscal 2024; net income was positive in 2 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Spero Therapeutics, Inc.'s shareholder treatment is put at 5.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 45% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE 15%: 15¢ of profit per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Spero Therapeutics, Inc. earned about 15 cents of profit for every dollar of shareholders' money. Leverage: it owed about 14 cents per dollar of assets, and net share issuance: its share count grew 9.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 36% of 315 in its family; net margin 12.8%.
From the record
Spero Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $67 million in fiscal 2025 ranks in the top 40% by size; a net margin of 12.8% ranks in the top 15%; revenue growth of 7.7% a year over the last 3 filed years ranks in the bottom 49% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 48% of 315 in its family for leadership.
From the record
Spero Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 12 officers and directors filing in the last fifteen months have been on the record a median of 7.2 years (top 26%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (bottom 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 40% of 273 in its family for room to expand.
From the record
Spero Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $40 million against no long-term debt tagged leaves 58.4% of its assets as net cash, top 28% of its family; cash from operations less capital spending is -18.9% of revenue (top 37%); research spending of 57.6% of revenue (bottom 44%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 49% of 306 in its family for growth drivers.
From the record
Spero Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 7.7% a year over the last three filed years against 80.1% over all 10, slowing (bottom 8% of its family); the newest year grew 39.3% (top 29%); research spending grew -6.8% a year (bottom 36%); capital spending grew 79.8% a year (top 11%) (its annual reports). Spero Therapeutics, Inc. reported 3 product lines in fiscal 2025: Collaboration Revenue Related Party at $47 million (70%), Collaboration Revenue at $13 million (19%), Grant Revenue at $7 million (11%); 2 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 22% of 233 in its family for expectations against reality.
From the record
Spero Therapeutics, Inc.'s newest year against its own record: revenue of $67 million in fiscal 2025 came in 47% above the $45 million its prior three years' pace pointed to (top 20% of its family); net income of $9 million against a prior three-year average of $31 million (top 12%); a net margin of 12.8% against -69.2% before (top 34%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made